Exodus of young scientists from academia reaching 'tipping point'; Biogen names new CEO

Faculty are struggling to hire postdocs, delaying research projects and pressuring universities to consider improving salaries and benefits. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by        'The tipping point is coming': Unprecedented exodus of young life scientists is shaking up academia By Jonathan Wosen Thumy Phan for STAT "When you try to calculate your hourly wage, it's sub-minimum wage, which is just ridiculous," said a Ph.D. student at UC San Diego. Read More STAT+: Biogen appoints former Sanofi executive Christopher Viehbacher as CEO By Matthew Herper and Damian Garde and Adam Feuerstein Michel Euler/AP Viehbacher, 62, will take the reins Monday, succeeding CEO Michel Vounatsos, who announced his impending resignation in May. Read More U.S. set to face third Covid winter, this time without key tools and treatments By Andrew Joseph and Jason Mast Spencer Platt/Getty Images Less Covid tracking. Fewer tests. And new variants are undercutting the power of the remaining antibody therapies for high-risk people. Read More Sponsored Insight by Genentech Perspectives in Alzheimer's disease Alzheimer's disease is one of the greatest global public health crises facing society today, and the need for new diagnostics and treatment approaches continues to grow. Learn more about how we're advancing the science, care, and treatment of this complex disease. Legal at one clinic, illegal at another: How abortion bans make gestational age even less precise By Eric Boodman Illustration: STAT; Photo: Courtesy Stephanie Dworak Laws that ban abortion after a certain gestational age miss an important nuance: it's an imprecise calculation that can change over time. Read More STAT+: For its first two medicines, EQRx abandons its bold strategy to lower drug prices By Matthew Herper Adobe The company's announcement stands in stark contrast to the approach it indicated it would take three years ago. Read More Colorado poised to become second state with legalized 'medicinal psychedelics' By Olivia Goldhill Michael Ciaglo/Getty Images Colorado would be the second state to legalize magic mushrooms, following Oregon's 2020 passage of a similar ballot question. Read More STAT+: Jeff Jonas leaves Sage Therapeutics to launch biotech incubator By Allison DeAngelis Jessica Rinaldi/The Boston Globe Jonas’ next step came to light on Thursday, when CBC announced that it has hired Jonas to lead a new biotech incubator called ABiox-X. Read More STAT+: PACT Pharma's personalized cancer treatments, powered by CRISPR, clear early safety hurdles By Megan Molteni Adobe The Phase 1 trial found that the personally formulated gene-edited immune cells didn’t cure patients, but they didn’t kill anyone either. Read More Listen: Biogen's new CEO, how the midterms affect science, & a biotech bankruptcy By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT Washington correspondent Sarah Owermohle joins us to explain how this week's midterm elections will affect health and medicine. Read More Thursday, November 10, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser